Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 24

1.

The MYCN enigma: significance of MYCN expression in neuroblastoma.

Tang XX, Zhao H, Kung B, Kim DY, Hicks SL, Cohn SL, Cheung NK, Seeger RC, Evans AE, Ikegaki N.

Cancer Res. 2006 Mar 1;66(5):2826-33.

PMID:
16510605
[PubMed - indexed for MEDLINE]
Free Article
2.

Prognostic significance of MYCN oncogene expression in childhood neuroblastoma.

Bordow SB, Norris MD, Haber PS, Marshall GM, Haber M.

J Clin Oncol. 1998 Oct;16(10):3286-94. Review.

PMID:
9779703
[PubMed - indexed for MEDLINE]
Free Article
3.

Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.

Warnat P, Oberthuer A, Fischer M, Westermann F, Eils R, Brors B.

BMC Cancer. 2007 May 25;7:89. Review.

PMID:
17531100
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

The MYCN oncogene and differentiation in neuroblastoma.

Westermark UK, Wilhelm M, Frenzel A, Henriksson MA.

Semin Cancer Biol. 2011 Oct;21(4):256-66. doi: 10.1016/j.semcancer.2011.08.001. Epub 2011 Aug 9. Review.

PMID:
21849159
[PubMed - indexed for MEDLINE]
5.

Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group.

George RE, Variend S, Cullinane C, Cotterill SJ, McGuckin AG, Ellershaw C, Lunec J, Pearson AD; United Kingdom Children Cancer Study Group.

Med Pediatr Oncol. 2001 Jan;36(1):169-76. Review.

PMID:
11464876
[PubMed - indexed for MEDLINE]
6.

MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis.

Slack A, Lozano G, Shohet JM.

Cancer Lett. 2005 Oct 18;228(1-2):21-7. Review.

PMID:
15927364
[PubMed - indexed for MEDLINE]
7.

MYCN oncoprotein targets and their therapeutic potential.

Bell E, Chen L, Liu T, Marshall GM, Lunec J, Tweddle DA.

Cancer Lett. 2010 Jul 28;293(2):144-57. doi: 10.1016/j.canlet.2010.01.015. Epub 2010 Feb 13. Review.

PMID:
20153925
[PubMed - indexed for MEDLINE]
8.

MYCN in neuronal tumours.

Schwab M.

Cancer Lett. 2004 Feb 20;204(2):179-87. Review.

PMID:
15013217
[PubMed - indexed for MEDLINE]
9.

Gene profiling of high risk neuroblastoma.

Vasudevan SA, Nuchtern JG, Shohet JM.

World J Surg. 2005 Mar;29(3):317-24. Review.

PMID:
15706435
[PubMed - indexed for MEDLINE]
10.

Favorable histology, MYCN-amplified 4S neonatal neuroblastoma.

Chan EL, Harris RE, Emery KH, Gelfand MJ, Collins MH, Gruppo RA.

Pediatr Blood Cancer. 2007 Apr;48(4):479-82. Review.

PMID:
16333837
[PubMed - indexed for MEDLINE]
11.

Genes co-amplified with MYCN in neuroblastoma: silent passengers or co-determinants of phenotype?

Scott D, Elsden J, Pearson A, Lunec J.

Cancer Lett. 2003 Jul 18;197(1-2):81-6. Review.

PMID:
12880964
[PubMed - indexed for MEDLINE]
12.

Neuroblastoma: the impact of biology and cooperation leading to personalized treatments.

Owens C, Irwin M.

Crit Rev Clin Lab Sci. 2012 May-Jun;49(3):85-115. doi: 10.3109/10408363.2012.683483. Review.

PMID:
22646747
[PubMed - indexed for MEDLINE]
13.

Nitric oxide control of MYCN expression and multi drug resistance genes in tumours of neural origin.

Porro A, Chrochemore C, Cambuli F, Iraci N, Contestabile A, Perini G.

Curr Pharm Des. 2010;16(4):431-9. Review.

PMID:
20236072
[PubMed - indexed for MEDLINE]
14.

The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification.

Hogarty MD.

Cancer Lett. 2003 Jul 18;197(1-2):173-9. Review.

PMID:
12880978
[PubMed - indexed for MEDLINE]
15.

MYCN deregulation as a potential target for novel therapies in rhabdomyosarcoma.

Morgenstern DA, Anderson J.

Expert Rev Anticancer Ther. 2006 Feb;6(2):217-24. Review.

PMID:
16445374
[PubMed - indexed for MEDLINE]
16.

Neuroblastoma: biological insights into a clinical enigma.

Brodeur GM.

Nat Rev Cancer. 2003 Mar;3(3):203-16. Review.

PMID:
12612655
[PubMed - indexed for MEDLINE]
17.

Diagnostic and scientific applications of TaqMan real-time PCR in neuroblastomas.

Dötsch J, Repp R, Rascher W, Christiansen H.

Expert Rev Mol Diagn. 2001 Jul;1(2):233-8. Review.

PMID:
11901819
[PubMed - indexed for MEDLINE]
18.

MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics.

Stallings RL.

Curr Pharm Des. 2009;15(4):456-62. Review.

PMID:
19199973
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Cellular kinetics of neuroblastoma and the role of surgery.

Kuroda T.

Pediatr Surg Int. 2011 Sep;27(9):913-7. doi: 10.1007/s00383-011-2949-6. Epub 2011 Jul 19. Review.

PMID:
21769682
[PubMed - indexed for MEDLINE]
20.

Alternative TrkAIII splicing: a potential regulated tumor-promoting switch and therapeutic target in neuroblastoma.

Tacconelli A, Farina AR, Cappabianca L, Gulino A, Mackay AR.

Future Oncol. 2005 Oct;1(5):689-98. Review.

PMID:
16556046
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk